However, for locally advanced tumors, such as tumor diameter > 5 cm, axillary lymph node metastasis, or poor molecular type (such as HER-2-positive or triple-negative); or for patients with a ratio of tumor size to breast volume that makes it difficult to preserve breasts, preoperative neoadjuvant drug therapy is often favored to achieve tumor down-staging and reduce recurrence rate in order to prolong patient survival (3). The gene discussed is ERBB2; the disease is neoplasm.